nabilone (cesamet) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Nabilone is a synthetic cannabinoid approved under the brand name cesamet for treatment of severe nausea and vomiting associated with cancer chemotherapy. Nabilone is an orally active which, like other cannabinoids, has complex effects on the central nervous system (CNS). It has been suggested that the antiemetic effect of nabilone is caused by interaction with the cannabinoid receptor system, i.e. the CB (1) receptor, which has been discovered in neural tissues.   NCATS

Chemistry

  • SMILES: CCCCCCC(C)(C)C1=CC(O)=C2[C@@H]3CC(=O)CC[C@H]3C(C)(C)OC2=C1
  • InChIKey: GECBBEABIDMGGL-RTBURBONSA-N
  • Mol. Mass: 372.5408
  • ALogP: 6.26
  • ChEMBL Molecules:
    nabilone  
    cesamet  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Alternative names

3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a- hexahydro-1-hydroxy-6,6-dimethyl-9h-dibenzo(b,d)pyran-9-one | cesamet | cesemat | cpd 109514 | cpd-109514 | lilly 109514 | lilly brand of nabilone | ly 109514 | ly-109514 | nabilon | nabilona | nabilone | nabilone, (6ar-trans)-isomer | nabilone, (6as-trans)-isomer | nabilone, (cis-(+-))-isomer | nabilone, (trans-(+-))-isomer | nabilonum

Organizations (28)

Research & Development (26)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (41)

Approved Indications (4)


 

Chronic Pain

Nausea (approved 1985)

Neoplasms

Postoperative Nausea and Vomiting

Experimental Indications - Clinical Trial Phases 1-4 (39)


 

Aggression (Phase 1)

Alzheimer Disease (Phase 3)

Anorexia (Phase 2/Phase 3)

Antineoplastic Combined Chemotherapy Protocols (Phase 4)

Anxiety (Phase 3)

Aphasia, Primary Progressive (Phase 2)

Body Weight (Phase 2/Phase 3)

Cachexia (Phase 2/Phase 3)

Cannabis (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2/Phase 3)

Dementia (Phase 2)

Developmental Disabilities (Phase 1)

Diabetic Neuropathies (Phase 4)

Fibromyalgia (Phase 2)

Frontal Lobe (Phase 2)

Frontotemporal Dementia (Phase 2)

Healthy Volunteers (Phase 4)

Intellectual Disability (Phase 1)

Kidney Failure, Chronic (Phase 3)

Marijuana Abuse (Phase 2/Phase 3)

Marijuana Smoking (Phase 2/Phase 3)

Multiple Sclerosis (Phase 4)

Nausea (Phase 4)

Neuralgia (Phase 4)

Obesity (Phase 2)

Obsessive-Compulsive Disorder (Phase 1/Phase 2)

Oxidative Stress (Phase 2/Phase 3)

Pain (Phase 2/Phase 3)

Parkinson Disease (Phase 3)

Peripheral Nervous System Diseases (Phase 4)

Phantom Limb (Phase 2)

Postoperative Nausea and Vomiting (Phase 2)

Problem Behavior (Phase 1)

Pruritus (Phase 3)

Sleep Initiation and Maintenance Disorders (Phase 2)

Spinal Cord Injuries (Phase 2)

Stress Disorders, Post-Traumatic (Phase 1/Phase 2)

Suicidal Ideation (Phase 2)

Weight Loss (Phase 2/Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 32
  • # of Trial Organizations: 26

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue